Overview

* Neurocrine Q2 2025 rev grows 17% yr/yr, adjusted EPS beats analyst expectations, per LSEG data

* Company narrows 2025 net product sales guidance for INGREZZA to $2.5 - $2.55 bln

* Co's strong Q2 performance driven by demand for INGREZZA and CRENESSITY

Outlook

* Neurocrine narrows 2025 INGREZZA sales guidance to $2.5-$2.55 bln

* Company expects strong demand for CRENESSITY to continue

* Company forecasts 2025 GAAP SG&A expenses of $1,135-$1,155 mln

Result Drivers

* INGREZZA DEMAND - Strong patient demand and expanded formulary access drove 15% sequential growth in INGREZZA sales

* CRENESSITY LAUNCH - Robust demand for CRENESSITY with $53 mln in sales and 664 new patient enrollment forms

* PIPELINE ADVANCEMENT - Neurocrine advancing neuropsychiatry pipeline with ongoing programs in major depressive disorder and schizophrenia

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $624.40

Product mln

Sales

Q2 Beat $1.65 $0.95

Adjusted (19

EPS Analysts

)

Q2 EPS $1.06

Q2 Beat $166.20 $100.10

Adjusted mln mln (16

Net Analysts

Income )

Q2 Net $107.50

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Neurocrine Biosciences Inc ( NBIX ) is $163.00, about 17.7% above its July 29 closing price of $134.19

* The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)